Skip to main content


  • Meeting abstract
  • Open Access

Osteoprotegerin (OPG) gene therapy in animal models of osteoarticular disease

  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1 and
  • 1
Arthritis Research & Therapy20013 (Suppl 1) :P5

  • Received: 6 April 2001
  • Published:


  • Inhibit Osteoclast Formation
  • Appendicular Bone
  • Soluble Decoy Receptor
  • Adult Female Mouse
  • Osteoarticular Disease

The soluble decoy receptor osteoprotegerin (OPG) regulates bone resorption by inhibiting osteoclast formation, function and survival. We investigated OPG gene therapy as a means of ameliorating chronic osteoarticular disease using a mouse ovariectomy (OVX) model of estrogen deficiency-induced osteoporosis (Mol Ther 2001, 3:1–9). Young adult female mice injected once with an adenoviral (Ad) vector carrying a human fusion protein combining the OPG ligand-binding and immunoglobulin constant domains (hOPG-Fc) developed serum OPG levels that exceeded the threshold needed for efficacy (as assessed by a marked increase in bone density) for over 12 months. The extent of OPG production and skeletal enhancement was titer-dependent. Mice subjected to OVX or sham surgery and then treated with Ad-hOPG-Fc had significantly more bone volume and fewer osteoclasts in axial and appendicular bones after 4 weeks. In contrast, animals given OVX and either a control vector expressing β-galactosidase or vehicle had significantly less bone than did comparably treated, sham-operated mice. This study confirms that a single Ad gene transfer can produce persistent high-level OPG expression and shows that OPG gene therapy may prove useful in treating osteoporosis. We anticipate that OPG gene therapy will offer similar promise as a bone-sparing agent in chronic arthritis since we have shown previously that injected OPG significantly inhibits skeletal erosion in the Lewis rat model of mycobacterial-induced adjuvant arthritis (Nature 1999, 402:304–309).

Authors’ Affiliations

Amgen, Thousand Oaks, CA, USA


© BioMed Central Ltd 2001